In this study, the authors assess their institutional experience of men who underwent an mpMRI and TPM following an initially negative TRUS prostate biopsy. In a 3-year period, there were 70 patients who met the study criteria; median age was 66 years (43–81) years and median prostate-specific antigen (PSA) 9.6 ug/L (0.7–33.9).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
At the end of the day, this implies that 40% of PCa diagnoses were discordant with mpMRI findings. An important conclusion that the authors draw is that a targeted biopsy in the absence of a concurrent systematic 12-core biopsy is not appropriate in this population.
However, this is a small population of selected patients. A trial of patients, similar to the PROMIS study,1 which was done in biopsy naïve patients, would be better able to answer this question. While I agree with the authors that a systematic biopsy is still warranted on repeat biopsy to evaluate for cancers not detectable on MRI, further evidence is required.
Presented By: Ewan Semple, Core Surgical Trainee, Department of Urology, Ninewells Hospital, Dundee, United Kingdom
Co-Authors: Hassen Ahmeidat, Ghulam Nabi, Ghulam M Nandwani
Institutions: Ninewells Hospital, NHS Tayside, Dundee, United Kingdom
Written By: Thenappan Chandrasekar, MD (Clinical Fellow, University of Toronto Twitter: @tchandra_uromd at the 72nd Canadian Urological Association Annual Meeting - June 24 - 27, 2017 - Toronto, Ontario, Canada
1. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP7, Oldroyd R, Parker C, Emberton M; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.